45.82

4.59% 2.01

Pre-market: 47.20 1.38 +3.01%

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $45.82, with a volume of 652.31K. It is up +4.59% in the last 24 hours and down -12.17% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Previous Close:

$43.81

Open:

$44.7

24h Volume:

652.31K

Relative Volume:

2.53

Market Cap:

$2.89B

Revenue:

Net Income/Loss:

$-80.77M

P/E Ratio:

-36.08

EPS:

-1.27

Net Cash Flow:

$-80.80M

1W Performance:

-1.46%

1M Performance:

-12.17%

6M Performance:

+2.41%

1Y Performance:

-14.40%

1-Day Range:

$44.10

$47.02

1-Week Range:

$41.27

$49.06

52-Week Range:

$37.55

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	45.82	2.89B	0	-80.77M	-80.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

Jan 21, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6.3%Here's What Happened - MarketBeat

Jan 21, 2025

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN

Jan 21, 2025

Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Jan 21, 2025

Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Jan 21, 2025

Jan 20, 2025

Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media

Jan 20, 2025

Jan 18, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpHere's Why - MarketBeat

Jan 18, 2025

MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN

Jan 18, 2025

Jan 17, 2025

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha

Jan 17, 2025

Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN

Jan 17, 2025

This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net

Jan 17, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat

Jan 17, 2025

Jan 16, 2025

MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks

Jan 16, 2025

How the (MLTX) price action is used to our Advantage - Stock Traders Daily

Jan 16, 2025

Jan 12, 2025

HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Jan 12, 2025

Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat

Jan 12, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jan 12, 2025

Jan 10, 2025

MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks

Jan 10, 2025

MLTX Crosses Below Key Moving Average Level - Nasdaq

Jan 10, 2025